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Edited by Beat ImhofAbstract We have recently demonstrated that dramatic alter-
ation in mucosal microvascular blood content termed early in-
crease in blood supply (EIBS) is a hallmark of early colon
carcinogenesis. In the current study, we elucidate the mechanism
of EIBS by assessing iNOS/nitric oxide axis in the histologically
normal colonic mucosa of rats treated with the colon-speciﬁc car-
cinogen, azoxymethane. We demonstrate that there was a strong
temporal correlation between EIBS and iNOS expression/activ-
ity. Importantly, we also observed that short-term treatment with
nitric oxide inhibitor abrogated EIBS. These data indicate that
iNOS induction may have a critical role in augmenting the pre-
dysplastic mucosal blood supply and thereby fostering colon car-
cinogenesis.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Microvasculature1. Introduction
The recent discovery of the role of the vascular alterations in
the colorectal cancer (CRC) has major biological and clinical
implications. Biologically, angiogenesis is essential to meet the
burgeoning metabolic needs of the growing colon cancer [1].
From a clinical perspective, suppressing angiogenesis with
agents such as bevacizumab (amonoclonal antibody to vascular
endothelial growth factor (VEGF)) causes profound regression
in CRC thus becoming a stalwart in the therapeutic armamen-
tarium [2]. While the importance of blood supply is unequivocal
in established CRCs, the carcinogenic stage at which it begins to
augment remains unclear. Previous studies indicate that micro-
vessel density is increased in small adenomas or even aberrant
crypt foci (ACF), the earliest morphological stages in colon car-qPresented in part at Digestive Disease Week meeting, May 14–19,
2005, Chicago, IL.
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doi:10.1016/j.febslet.2007.07.012cinogenesis [3–5]. However, there is limited information on
whether vascular abnormalities occur in the predysplastic mu-
cosa (i.e. carcinogenesis initiation). From a teleological perspec-
tive, one would expect increased mucosal blood supply at the
earliest stages given that the premalignant epithelium is hyper-
proliferative (resulting from ﬁeld carcinogenesis) [6] and
therefore hypermetabolic. However, the conventional method-
ologies have lacked the requisite ability to accurately quantify
the micro-circulation in the premalignant mucosa.
Our group has developed a novel optical technique, four
dimensional elastic light-scattering ﬁngerprinting (4D-ELF),
that allows heretofore unattainable quantitative assessment
of the epithelial microcirculation [7,8]. We have previously re-
ported that in the azoxymethane (AOM)-treated rat model of
colon carcinogenesis, there was an increase in pericryptal cap-
illary blood content that preceded the earliest morphological
manifestations of colon carcinogenesis [8]. We termed this phe-
nomenon as the early increase in blood supply (EIBS). While
immunoblot analysis of mucosal hemoglobin also conﬁrmed
EIBS, it was considerably less sensitive than the optical ap-
proach [8].
Using 4D-ELF we have been able to also document EIBS in
humans ex vivo (endoscopic biopsies) and more recently in situ
(using colonoscopically compatible 4D-ELF probe) studies [9].
Thus, while the concept of EIBS is ﬁrmly established in colon
carcinogenesis, one major unresolved question is the mecha-
nisms through which EIBS occurs. It has been shown that a
number of vascular modulating genes (cyclooxygenase 2, oste-
opontin, etc.) are overexpressed in the histologically normal
appearing mucosa of patients who harbor neoplasia elsewhere
in the colon [10]. However, the rapidity of the EIBS occurrence
would argue against neo-angiogenesis (insuﬃcient time for
new vessel formation). A more plausible hypothesis for EIBS
would be augmentation of blood ﬂow through dilation of
existing vessels (e.g. vasodilation).
Nitric oxide (NO) would represent an attractive potential
molecular candidate to mediate the putative vasodilation. In
CRC, NO can be produced by inducible nitric oxide synthase
(iNOS), which is known to be overexpressed in majority of
invasive colon cancers [11,12]. However, since little is known
about the timing of iNOS upregulation (and hence NO pro-
duction) in the early stages of colon carcinogenesis, it is un-
clear whether the timing of iNOS upregulation would be
consonant for its possible role as an EIBS mediator. In the
present study, we utilized AOM-treated rat model of colonblished by Elsevier B.V. All rights reserved.
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rally correlates with EIBS. Furthermore, we prove the causal-
ity of the two phenomena by observing that pharmacological
inhibition of iNOS abrogated EIBS.2. Materials and methods
2.1. Animal studies
All animal procedures were reviewed and approved by the Institu-
tional Animal Care and Use Committee for Evanston-Northwestern
Healthcare. Male Fisher 344 rats (150–200 g; Harlan, Indianapolis,
IN) were treated either with two injections (i.p.) of 15 mg/kg AOM
(Midwest Research Institute, Kansas City, MO) or saline. Based on
the experimental protocols, rats were euthanized either after 2 or 8
weeks of second AOM/saline injections. For the iNOS inhibition
experiment, animals seven weeks post second AOM/saline injections
were gavaged with a pharmacological NOS inhibitor, N6-nitro-L-argi-
nine-methyl ester (L-NAME) or vehicle once a day for 7 days. Colons
were removed and aliquots (matched between control and treatment
group) were subjected to 4D-ELF analysis within 2 h of harvest. Com-
parable sections were formalin ﬁxed and paraﬃn embedded for future
immunohistochemical analysis.2.2. 4D-ELF analysis
4D-ELF was used to measure blood content in the subepithelial
compartment [7,8]. Brieﬂy, a collimated beam of light (from a 75 W
xenon arc lamp and passed through a polarizer and a beam-splitter)
was allowed to illuminate approximately 10 sites on the distal mucosa
surface. The light scattered by the specimen was collected through the
beam-splitter, a lens, and a second polarizer into the detection system,
which consisted of a spectrograph coupled with a CCD (charge-cou-
pled device) camera. The instrument measured two polarization com-
ponents of scattered light: polarized parallel to the incident
polarization direction (co-polarized component) as well as polarized
perpendicular to the incident polarization direction (cross-polarized
component). The unique absorption spectrum of hemoglobin in the
visible range and the depth-selectivity of the diﬀerential polarization
signal enabled us to extract blood concentration in the superﬁcial mu-
cosa (50–100 lm below the mucosal surface) that corresponded to
the capillary plexus immediately below the epithelium. Detailed
descriptions and validations of the measurements of tissue blood con-
tent are published elsewhere [7,8,13].2.3. Immunohistochemical staining
Formalin ﬁxed and paraﬃn embedded colonic segments were sub-
jected to immunohistochemical analysis as described previously [14].
Brieﬂy, 5 lM paraﬃn-embedded sections was mounted on Superfrost+
slides (Vector Laboratories, Burlingame, CA), heated at 60 C for 1 h
and then deparaﬃnized with two 5 min washes of xylene followed by
series of graded ethanol washes. Antigen retrieval for iNOS, VEGF
and nitrotyrosine were accomplished by pressure microwaving (Nor-
dicWare, Minneapolis, MN) in antigen unmasking reagent (Vector
Laboratories) at high power setting for 9 min. Endogenous peroxidase
activity was quenched by 5 min wash in 3% H2O2 while the non-spe-
ciﬁc binding was blocked by 2 h incubation with 5% horse serum at
room temperature. Sections were then incubated overnight with pri-
mary antibodies [anti-VEGF (1:100) and anti-iNOS (1:200) from Santa
Cruz Biotechnology, CA; anti-nitrotyrosine (1:200) from Cayman
Laboratories, An Arbor, MI] followed by incubation with appropriate
biotinylated secondary antibodies. After three 5 min washings in PBS,
the specimen was further developed using Vectastatin Elite ABC kit
(Vector Laboratories). Staining intensity was measured on a ﬁve-point
scale (0, none; 1, equivocal; 2, low; 3, moderate; 4 and above intense)
by a gastrointestinal pathologist (J.H.) blinded to the treatment group.
2.4. Reverse-transcriptase polymerase chain reaction (RT-PCR)
We evaluated iNOS mRNA from colonic scrapings of rats two
weeks after carcinogen initiation. Brieﬂy, after euthanizing rats (both
AOM/saline treated), the colons were isolated, washed and opened lon-
gitudinally. The distal colonic mucosa was isolated through gentle
scraping with a microscope slide as previously described [15]. TotalRNA was extracted using TRI Reagent (Sigma). After DNase treat-
ment, cDNA synthesis and PCR ampliﬁcation for iNOS was carried
out using the RT-PCR kit (Invitrogen, CA) following the manufac-
turer’s protocol. RT-PCR expression was normalized to cyclophilin
expression.3. Results
3.1. iNOS but not VEGF increase at pre-ACF stage
Previous studies from our laboratory indicated that micro-
vascular blood content is augmented early in colon carcinogen-
esis (i.e. 2 weeks after AOM-injection) [8]. To keep this in
perspective, in this well-validated model of colon carcinogene-
sis, ACF typically develops at 4–6 weeks post carcinogen treat-
ment while adenomas typically require 20 weeks and
carcinomas 35–40 [8]. Thus, we assessed iNOS mRNA in
the colonic mucosal aliquots and found that it was markedly
induced at this early time point when compared to age-
matched control (saline-injected) rats (Fig. 1A).
We conﬁrmed this upregulation of iNOS protein through
immunohistochemcial analysis. Speciﬁcally, we noted a dra-
matic augmentation of iNOS protein in the colonic epithelium
of AOM-treated rats compared to age-matched control
(Fig. 1B). In order to support that this resulted in increased
nitric oxide production we assayed the tissue sections for
nitrotyrosine immunoreactivity. Nitrotyrosine residues are
produced by covalent interactions (peroxinitration) of nitric
oxide to protein and thus serve as a well validated surrogate
marker of iNOS activity [16]. We noted that nitrotyrosine in-
crease mirrored iNOS in the mucosa (data not shown).
We then assessed VEGF levels in the mucosa as a surrogate
marker for angiogenic status of the mucosa given that this is
the most powerful mediator of blood vessel formation in colon
carcinogenesis [17]. While there was colonic mucosal staining
noted, there was no evidence of alterations between AOM-
treated and control animals (Fig. 1B).3.2. iNOS expression/marker of activity temporally correlates
with EIBS
To further explore the role of iNOS in EIBS, we examined
the temporal correlation of these parameters. We ﬁrst assessed
EIBS and noted that this was also elevated at week 4 and in-
creased in magnitude by week 12 where it plateaued. There
was no signiﬁcant alteration in microvascular blood content
in the saline-treated animals over time and therefore the saline
controls are represented by a single composite measure
(Fig. 2a). This was paralleled by colonic mucosal iNOS protein
levels in AOM-treated rats when compared to age-matched
controls (Fig. 2b). In order to demonstrate that the induction
of iNOS actually lead to nitric oxide production, we probed
these specimens further for nitrotyrosine immunoreactivity.
We demonstrate that nitrotyrosine was markedly increased
at these early time points (3.0 fold over age-matched controls
at week 4) and continued relatively unabated at the later time
points (Fig. 2b).3.3. Pharmacological inhibition of iNOS abrogates EIBS
In order to establish that iNOS induction is in fact causal and
not simply correlated with EIBS, we studied the eﬀect of iNOS
inhibitor, L-NAME [18], on the microvascular blood content as
determined by 4D-ELF analysis in both the saline- and AOM-
Fig. 1. iNOS induction occurs in a temporally consonant with EIBS (previously demonstrated to be 2 weeks post-AOM, prior to ACF development
[8]). Fisher rats were euthanized 2 weeks after 2nd weekly injections of AOM (see Section 2) in (A), iNOS expression (by RT-PCR) was upregulated
in AOM-treated colons (by 2.5 fold; P = 0.02) compared to controls. Similarly as shown in (B), the protein expression (by IHC scoring intensity)
was signiﬁcantly upregulated in AOM rats (P < 0.05) compared to controls. However, at this stage no signiﬁcant change was observed in the
immunoreactivity of VEGF in AOM sample compared to controls.
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normalized AOM-induced blood content in the superﬁcial
mucosa to the control levels (P-value = 0.0034, compared to
superﬁcial blood content of AOM-treated rats gavaged
with vehicle-saline). Importantly, in the saline-treated rats,
L-NAME had no signiﬁcant eﬀect on microvascular blood con-
tent, suggesting that the eﬀect of L-NAME is speciﬁc to carci-
nogenesis associated microvascular blood content changes
and not simply a non-speciﬁc vasoconstriction (Fig. 3).0
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Fig. 2. iNOS induction/activity temporally correlates with the EIBS.
To determine the associations of EIBS and iNOS induction during the
carcinogenic progression animals were sacriﬁced serially at 4, 12 and
20 weeks post initiation (see text). EIBS was measured by 4D-ELF,
while iNOS and nitrotyrosine was quantiﬁed using immunohistochem-
istry. P values are compared to age-matched saline treated rats. All
time points in Fig. 2a were statistically signiﬁcant (P < 0.01).4. Discussion
We herein provide the ﬁrst mechanistic insights into the aug-
mentation of microvascular blood supply during early colonic
carcinogenesis. We demonstrate that increased expression of
iNOS is an early event in colon carcinogenesis that temporally
mirrors EIBS. Moreover, short-term use of the iNOS inhibitor,
L-NAME abrogated EIBS providing compelling evidence for
causality of the two phenomena. These studies were made pos-
sible through the technological breakthrough of 4D-ELF to
reliably identify and quantitate EIBS [7]. Speciﬁcally, 4D-
ELF allows probing the epithelial capillaries without contam-
ination from the deeper mucosal/submucosal arterioles/venules
[8]. Since EIBS is predominantly a mucosal capillary phenom-
enon (serving the metabolic needs of the hyperproliferative
mucosa), whereas most of the total blood supply resides dee-
per, gating of the superﬁcial mucosal capillaries is critical for
the identiﬁcation of EIBS. Indeed, while EIBS was also noted
by immunoblot analysis of hemoglobin, its magnitude was
considerably lower than that noted by 4D-ELF, because it is
essentially impossible to limit tissue scarping required for
immunoblot to the mucosal capillaries only [8].
Our current work provides the biological underpinnings for
the recently described phenomenon of EIBS. There is emerging
evidence to support the clinical and biological signiﬁcance of
EIBS. Speciﬁcally, EIBS has promise for a powerful marker
of ﬁeld carcinogenesis. In the initial studies conducted on
experimental models (AOM-treated rat and MIN mouse),
EIBS not only occurred prior to morphological markers (ade-
noma or ACF) but, importantly, it was conﬁned to the colonic
regions where future neoplasia would occur. EIBS is also a
hallmark of early colon carcinogenesis in humans as indicated
by our demonstration that microvascular blood content was
Fig. 2 (continued)
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Fig. 3. Short term treatment with L-NAME mitigated EIBS in AOM-
treated animals but had no eﬀect on the colonic microvascular blood
content in saline-treated rats (see text).
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patients harboring neoplasia when compared to those whowere neoplasia-free [19]. These ﬁndings have been bolstered
by our recent work utilizing an endoscopically compatible
4D-ELF probe which enables in situ EIBS measurements dur-
ing colonoscopy [9]. Using this approach, we have demon-
strated that the augmentation of microvascular blood
content extends within the third of the colon that harbors
the neoplasia (adenomatous polyps) and its magnitude mirrors
the proximity to the lesion.
The phenomenon of EIBS lends itself to several potential
applications. For instance the spatial correlation of EIBS to
tumors serves as a marker for the presence of neoplasia. We
are currently exploring its utility in both risk stratiﬁcation
and polyp identiﬁcation. Another application of EIBS may
be a biomarker for chemoprevention. It is well established that
the vasculature is a very eﬀective therapeutic target in estab-
lished colon cancers (e.g. bevacizumab) [2]. Recently, there
has been emerging interest in ‘‘angioprevention’’, inhibiting
vasculature-modulating proteins (e.g. cyclooxygenase 2,
AKT, osteopontin, nuclear factor kappa B) for chemopreven-
tion of colonic neoplasia [20,21].
Our data on iNOS expression and its pharmacological inhi-
bition, taken together, strongly support a role for iNOS induc-
tion in EIBS. A number of previous studies have mainly
focused on the role of iNOS in established colon cancer. For
H.K. Roy et al. / FEBS Letters 581 (2007) 3857–3862 3861example, iNOS has long been known to be upregulated in most
(80%) of all human and AOM-induced colon cancers [22,23].
It is noteworthy that iNOS expression has been shown to be an
independent prognostic marker of colon cancer [24]. However,
to date, there has been limited data on the levels of iNOS in
earlier stages of colon carcinogenesis. Rao and colleagues
had reported that iNOS activity was augmented at 8 weeks
post AOM injection (when ACF are well-established) [25].
Our data clearly indicate that iNOS is upregulated prior to
ACF development. While we did not explore the mechanisms
involved in iNOS regulation, there is evidence that protein ki-
nase C (PKC) may be involved in iNOS induction by deoxy-
cholate, a colon carcinogen [26]. Many groups, including our
own, have shown that induction of PKC in the histologically
normal mucosa is an early event in colon carcinogenesis [27].
Indeed, upstream regulators of PKC such as epidermal growth
factor receptor and phospholipase C have been shown to be in-
duced within 5 days of carcinogen treatment [28].
While there are numerous molecular/cellular consequences
of iNOS overexpression (e.g. production of mutagenic reactive
nitric oxide species), we believe that microvascular blood ﬂow
induction is of major importance in early colon carcinogenesis
in order to meet the metabolic needs of the hyperproliferative
epithelium. In support of the role of metabolic demand, our
in vivo data in humans demonstrated that the elevation in
deoxygenated hemoglobin concentration was more signiﬁcant
than that of the total (deoxygenated and oxygenated) hemo-
globin in the proximity of neoplasia [9]. Unfortunately, the
ex vivo nature of our present rat studies precluded the ability
to extract information about the oxygen status of hemoglobin.
Further supporting the role of blood supply in the initiation of
colon carcinogenesis is the demonstration that germline muta-
tion of the vascular modulator, endoglin, resulted in an in-
creased risk of colon carcinogenesis in humans [29].
The mechanism through which iNOS induces EIBS was not
directly investigated in this study. We believe that this most
likely represents increased ﬂow in existing blood vessels as
the vasodilatory ability of NO is well established. In addition,
the rapid reversal of EIBS with iNOS inhibitors would argue
against neo-angiogenesis and favor vasodilation. However,
several studies suggest that iNOS is also an important media-
tor of angiogenesis in colon cancer [30]. For instance, iNOS
expression closely correlates with the degree of angiogenesis
in colorectal cancers. The mechanisms remain unclear but
the ability of iNOS to induce cyclooxygenase 2 has been impli-
cated [31]. While our data strongly suggest that vasodilation is
responsible for pre-adenoma stage EIBS, this does not pre-
clude the possibility that angiogenesis may play a role at later
time points. However, it is interesting to note that studies from
murine cancers showed that iNOS inhibitors decreased ﬂow in
tumor blood vessels while there was no alterations in ﬂow
through non-neoplastic vessels [32]. This indicates that the
most plausible explanation is that EIBS is mediated through
NO-induced vasodilation.
There are several limitations to our study that need to be
acknowledged. The use of pharmacological inhibitors raises
potential concerns about speciﬁcity. However, there is a wealth
of evidence that L-NAME is a very speciﬁc suppressor of NO
production through competitive inhibition of NOS [33]. An-
other potential concern is that we did not assay the degree of
inhibition in colonic iNOS. However, the dosage selected
(100 ppm) is well established for colonic chemopreventivestudies with marked reduction in neoplasia [18]. While it is
possible that other nitric oxide synthase species may be in-
volved, we believe that given its role in colon carcinogenesis,
iNOS is clearly the most compelling molecular candidate.
In conclusion, we present herein the ﬁrst mechanistic in-
sights into the augmentation of microvascular blood content
in colon carcinogenesis. Speciﬁcally, we provide both correla-
tional and pharmacological inhibitor data to support the cen-
tral role of iNOS in governing EIBS. This important ﬁnding
has ramiﬁcations for understanding biology of colon carcino-
genesis and also potential clinical applications with regards
to early detection and chemoprevention.
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